Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - modified-release tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms. indications include:
lower respiratory tract infections for example bronchitis and pneumonia.
upper respiratory tract infections for example sinusitis and pharyngitis.
skin and soft tissue infections for example folliculitis, cellulitis and erysipelas.

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - clarithromycin - modified-release tablet - macrolides; clarithromycin

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: sorbitan mono-oleate; pregelatinised maize starch; titanium dioxide; povidone; propylene glycol; hypromellose; silicon dioxide; sorbic acid; stearic acid; purified talc; hyprolose; quinoline yellow; vanillin; magnesium stearate; croscarmellose sodium; microcrystalline cellulose - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: potassium sorbate; castor oil; titanium dioxide; hypromellose phthalate; maltodextrin; carbomer 934; citric acid; silicon dioxide; xanthan gum; sucrose; povidone; flavour - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: sorbic acid; hypromellose; hyprolose; sorbitan mono-oleate; vanillin; purified talc; silicon dioxide; stearic acid; quinoline yellow; propylene glycol; povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; microcrystalline cellulose - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 250mg;  ; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg   excipient: croscarmellose sodium hydrated silica hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc quinoline yellow   sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol   hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc purified water quinoline yellow   sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin - klacid tablets are indicated for treatment of infections caused by susceptible organisms. such infections include: · respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. · skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. · disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum, or mycobacterium kansasii. · prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. · clarithromycin in the presence of acid suppression is indicated for the treatment of duodenal ulcer and in reducing the rate of ulcer recurrence.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 500mg;  ; clarithromycin 500mg - film coated tablet - 500 mg - active: clarithromycin 500mg   excipient: croscarmellose sodium hydrated silica hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc quinoline yellow sorbic acid sorbitan oleate stearic acid titanium dioxide vanillin active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol   hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc purified water quinoline yellow sorbic acid sorbitan oleate stearic acid titanium dioxide vanillin - klacid tablets are indicated for treatment of infections caused by susceptible organisms. such infections include: · respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. · skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. · disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum, or mycobacterium kansasii. · prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. · clarithromycin in the presence of acid suppression is indicated for the treatment of duodenal ulcer and in reducing the rate of ulcer recurrence.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 50 mg/ml;   - granules for oral suspension - 250 mg/5ml - active: clarithromycin 50 mg/ml   excipient: carbomer castor oil citric acid monohydrate hydrated silica hypromellose phthalate fruit mix flavour maltodextrin potassium sorbate povidone sucrose titanium dioxide xanthan gum - klacid suspension is indicated for treatment of infections caused by susceptible organisms. such infections include: ? upper respiratory infections (e.g. streptococcal pharyngitis). ? lower respiratory infections (e.g. bronchitis, pneumonia). ? acute otitis media. ? skin and skin structure infections (e.g. impetigo, folliculitis, cellulitis, abscesses). ? disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 500mg;   - powder for injection - 500 mg - active: clarithromycin 500mg   excipient: lactobionic acid sodium hydroxide - klacid i.v. is indicated whenever parenteral therapy is required for treatment of sensitive microorganisms in the following conditions: · upper respiratory tract infections. · lower respiratory tract infections. · skin and soft tissue infections.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - clarithromycin -